A long-term response to nivolumab in a case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages

Hiromi Watanabe, Kadoaki Ohashi, Kazuya Nishii, Keisuke Seike, Go Makimoto, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Anti-programmed cell death 1 (PD-1) antibodies have poor efficacy in epidermal growth factor receptor (EGFR)-mutated lung cancer. We herein report a 72-year-old man with programmed cell death-ligand 1 (PDL1)- negative lung adenocarcinoma harboring an EGFR mutation that responded to nivolumab for more than 2 years. A pathological examination revealed infiltration of CD8-positive lymphocytes and macrophages expressing CD68, CD206, and PD-L1 into the PD-L1-negative tumor; CD206 expression is a marker of immunosuppressive tumor-associated macrophages (TAMs). The presence of PD-L1-positive TAMs in the tumor environment might be a predictor of a positive response to anti-PD-1 antibodies.

Original languageEnglish
Pages (from-to)3033-3037
Number of pages5
JournalInternal Medicine
Volume58
Issue number20
DOIs
Publication statusPublished - 2019

Keywords

  • EGFR mutations
  • Lung adenocarcinoma
  • Nivolumab
  • Tumor-associated macrophages

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'A long-term response to nivolumab in a case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages'. Together they form a unique fingerprint.

  • Cite this